PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops From Its Proprietary OPC Platform at ARVO 2024
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops From Its Proprietary OPC Platform at ARVO 2024
- Presentation at ARVO 2024 gained attention as Eylea (aflibercept) eye drops demonstrated similar efficacy to intravitreal injections in animal studies.
- 在動物研究中，Eylea（aflibercept）滴眼液顯示出與玻璃體內注射相似的功效，因此在ARVO 2024上的演示引起了人們的關注。
DAEJEON, South Korea , May 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced that its U.S. subsidiary, Wincal Biopharm, Inc. ("WincalBio"), gained agreat attention at the world's largest ophthalmology conference, Association for Research in Vision and Ophthalmology 2024 (ARVO 2024), when they presented the preclinical data of the eye drop formulation.
韓國大田，2024 年 5 月 22 日 /PRNewswire/ — PharmabCine, Inc.（“PharmabCine” 或 “公司”）（KOSDAQ： 208340）是一家處於臨床階段的上市公司，開發用於治療未滿足的醫療需求的下一代療法。該公司宣佈，其美國子公司Wincal Biopharm, Inc.（“WincalBio”）在全球最大的眼科會議——2024年視覺與眼科研究協會（ARVO 2024）上獲得了高度關注，當時他們展示了眼藥水配方的臨床前數據。
WincalBio revealed that currently marketed therapeutic antibodies can be delivered within the eyes using their proprietary Ocular Penetration Carrier (OPC) screening platform, as shown by animal studies. This innovation suggests that non-invasive eye drops could potentially replace traditional intravitreal injection methods for treating eye diseases.
WincalBio透露，動物研究表明，目前上市的治療性抗體可以使用其專有的眼穿透載體（OPC）篩查平台在眼內輸送。這項創新表明，非侵入性眼藥水有可能取代傳統的玻璃體內注射方法來治療眼部疾病。
The OPC screening platform was developed to identify antibody-carrier complexes capable of delivering therapeutic agents into the back of the eye, such as the vitreous, retina, and choroid, without relying on needle injections. This allows patients to administer treatment conveniently at home using eye drops. The key to this technology is finding a matching carrier to each antibody to facilitate drug delivery inside the eye.
開發OPC篩查平台的目的是識別能夠在不依賴針頭注射的情況下將治療藥物輸送到眼後（例如玻璃體、視網膜和脈絡膜）的抗體載體複合物。這使患者可以在家中使用眼藥水方便地進行治療。這項技術的關鍵是爲每種抗體找到匹配的載體，以促進藥物在眼內輸送。
At ARVO 2024, WincalBio gave an oral presentation that their OPC screening platform enabled the delivery of the anti-VEGF treatments, Eylea (aflibercept) and Beovu (brolucizumab), as eye drops. In a laser-induced choroid neovascularization (CNV) mouse model, the OPC eye drop formulations demonstrated significant reduction in lesion size and vascular leakage, showing similar efficacy to the intravitreal injections. This breakthrough received huge interest and enthusiasm from the meeting participants.
在2024年的ARVO上，WincalBio做了口頭陳述，稱他們的OPC篩查平台使抗血管內皮生長因子療法Eylea（aflibercept）和Beovu（brolucizumab）作爲滴眼劑提供抗血管內皮生長因子療法。在激光誘導脈絡膜新生血管（CNV）小鼠模型中，OPC滴眼液配方顯示病變大小和血管滲漏顯著減少，表現出與玻璃體內注射相似的療效。這一突破引起了與會者的極大興趣和熱情。
Dr. Venice Chiueh, Project leader and Director at WincalBio, stated that "Developing eye drop formulations is crucial for enhancing patient convenience and reducing the patient's reluctance to receiving treatment. We are committed to achieving successful outcomes not only in upcoming primate efficacy studies but also in clinical trials."
WincalBio項目負責人兼董事Venice Chiueh博士表示：“開發眼藥水配方對於提高患者的便利性和減少患者不願接受治療的情緒至關重要。我們不僅致力於在即將到來的靈長類動物療效研究中取得成功結果，還致力於在臨床試驗中取得成功結果。”
Dr. TaeWeon Lee, Chief Scientific Officer at WincalBio, added, "These research results are expected to positively impact VC investment opportunities as well as corporate partnerships with biopharma companies with intravitreal therapeutics or planned launch of biosimilars. Our aim is to extend this innovative technology beyond the anti-VEGFantibodies to various eye disease treatments, allowing patients to receive moreconvenient and accessible care."
WincalBio首席科學官TaeWeon Lee博士補充說：“這些研究結果預計將對風險投資機會以及與採用玻璃體內療法或計劃推出的生物仿製藥的生物製藥公司的企業合作伙伴關係產生積極影響。我們的目標是將這項創新技術從抗血管內皮生長因子抗體擴展到各種眼病治療方法，讓患者獲得更便捷和更容易獲得的護理。”
SOURCE PharmAbcine
來源 PharmabCine
譯文內容由第三人軟體翻譯。